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Abstract
Partnerships between researchers and policymakers can improve uptake and integration of scientific evidence. This article 
describes the research-policy partnership between the international epidemiology Databases to evaluate AiDS (ieDeA) 
(www.iedea.org) and the world Health Organization (wHO), which was established in 2014. ieDeA is an international 
research consortium, which analyses data on almost 2 million people living with Hiv under care in routine settings in 
46 countries in Asia-Pacific, the Caribbean, Central and South America, North America and sub-Saharan Africa. Five 
multiregional analyses were identified to inform the wHO on progress towards the second and third 90s of the 90-90-
90 targets in adults and children: (i) trends in CD4 cell counts at the start of antiretroviral therapy (ART); (ii) delays 
from enrolment in Hiv care to ART initiation; (iii) the impact of ART guideline changes; (iv) retention in care, mortality 
and loss to follow-up; and (v) viral suppression within the first 3 years after initiating ART. Results from these analyses 
were contributed to the 2015 and 2016 wHO global Hiv progress reports, will contribute to the 2018 report, and were 
published in academic journals. The partnership has been mutually beneficial: discussion of wHO policy agendas led to 
more policy-framed, relevant and timely ieDeA research, and the collaboration provided the wHO with timely access to 
the latest data from ieDeA, as it was shared prior to peer-review publication.
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Background
Over the past decade, the world Health Organization (wHO) has 
published a series of global Hiv progress reports, documenting 
the successes and challenges of the massive antiretroviral therapy 
(ART) scale-up in resource-limited settings that resulted in nearly 
21 million people receiving ART by mid-2017 [1–5]. National 
governments, international donor agencies, and implementing 
agencies use these reports to assess progress and reorient priori-
ties. The wHO also supports ART scale-up through a series of 
evidence-based recommendations, ranging from standardising 
ART regimens to promoting service delivery models to assist people 
living with Hiv, healthcare workers and country-level policymak-
ers, in making informed decisions about healthcare interventions 
[6–9].
wHO progress reporting and evidence-based guidelines aim to 
translate and incorporate the best available research evidence 
into well-informed guidelines and recommendations [6,7,10]. 
However, production and dissemination of scientific evidence 
does not necessarily lead to its integration into policy [11,12]. 
Partnerships between researchers and policymakers can facilitate 
and improve uptake and integration of scientific evidence [12–16]. 
Communication between stakeholders allows researchers to be 
aware of policy-related evidence gaps and upcoming policy pri-
orities, leading to more pertinent and opportune policy-relevant 
research [10,14,17]. Such research-policy partnerships can also 
provide the opportunity for critical information to be communi-
cated rapidly and prior to completion of the often lengthy peer-
review and publication process.
This article summarises the process, output and challenges of a 
research-policy partnership between the international epidemiology 
Databases to evaluate AiDS (ieDeA) and the wHO that aims to 
formalise and facilitate uptake and integration of ieDeA scientific 
evidence into wHO ART progress reporting and Hiv health policy 
development.
The International epidemiology Databases to 
Evaluate AIDS (IeDEA)
ieDeA (www.iedea.org) is an international research consortium 
of Hiv cohorts funded by the National institutes of Health (NiH) 
since 2006 [18–20]. ieDeA pools existing clinical and epidemio-
logical data on people living with Hiv under care in routine 
settings as a cost-effective way of generating large data sets to 
address high priority and evolving research questions in Hiv/
AiDS treatment and care. The seven regions included in ieDeA 
are: Asia-Pacific; the Caribbean, Central and South America 
(CCASA); North America; and four regions in Africa (Figure 1). 
Across these regions, ieDeA has individual-level data on over 
1.7 million patients from over 480 clinic and research centres in 
46 countries, in both high- and low-Hiv burden settings.
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Figure 1. Map of the regions of ieDeA. Adapted from www.iedea.org. CCASAnet: Caribbean, Central and South America; NA-ACCORD: North America.
and 90% of all people receiving ART are virally suppressed by 
2020 [27]. These fast-track targets aimed to improve the Hiv 
cascade of care with the goal of ending the AiDS epidemic as a 
public health threat by 2030 [27]. in the following year, wHO 
released the ‘treat all’ guideline update, recommending immediate 
ART for all people living with Hiv, eliminating prerequisites for 
initiating treatment [28].
The collaboration commenced with a face-to-face meeting at the 
wHO headquarters in Geneva, Switzerland in November 2014, 
where four members of the wHO Department of Hiv/AiDS and 
four investigators of the ieDeA Southern Africa team based in 
Bern, Switzerland, discussed potential collaborative work. Four 
video conference calls were subsequently held in early February 
2015 to discuss analyses that the ieDeA consortium could under-
take to support the wHO 2015 global Hiv progress report. each 
call had between 10 and 12 participants from the seven ieDeA 
regions, the NiH-funding institutions and the wHO. Later that 
month, during the ieDeA Scientific Symposium at the Conference 
on Retroviruses and Opportunistic infections (CROi), attended 
by more than 20 ieDeA investigators representing every ieDeA 
region, the ieDeA consortium agreed to undertake this col-
laboration with the wHO, and identified five core multiregional 
cascade analyses and the teams that would undertake them. These 
cascade analyses aimed to inform the wHO on progress towards 
the 90-90-90 targets, guideline implementation and trends in 
the epidemic, using routinely collected ieDeA programme data 
(Table 1).
ieDeA-wHO analyses
Cohorts cannot provide information on the number of people 
living with Hiv or the number who know their status in their 
settings, so the collaboration is unable to assess the first 90 
(percentage knowing their status). The ieDeA collaboration can, 
however, examine how quickly patients are started on ART after 
linkage to care and enrolment at their clinics, and how many of 
those who start ART have stopped treatment (the second 90 
target), while those cohorts that collect routine viral load data 
can also assess the third 90 target. with more than 15 years of 
ieDeA collects routine data from both urban and rural settings, 
in primary through tertiary care facilities, and from small private 
clinics to large programmes run by national health systems. Patient 
information, clinic visit history, laboratory measurements, medica-
tions and clinical outcomes are some of the data collected by 
ieDeA regional cohorts. Regional cohorts do not collect data 
through a single standardised protocol, so ieDeA implements a 
prospective data exchange standard (www.ieDeADeS.org) for a 
selection of existing data – based on the Hiv Cohorts Data 
exchange Protocol (www.hicdep.org) – to facilitate sharing and 
merging of data across ieDeA regions. A series of site assessment 
surveys obtain up-to-date information on facility policies and 
procedures and the clinical and support services provided to Hiv 
patients enrolled at ieDeA clinics [21–26]. ieDeA is also a network 
of epidemiologists, clinicians, statisticians and data management 
specialists, who participate in topic-specific working groups to 
foster collaboration between regional cohorts, facilitate data 
harmonisation and dissemination, and advance the international 
Hiv scientific research agenda.
The IeDEA-WHO collaboration
The ieDeA-wHO collaboration was launched at the end of 2014, 
after more than a decade of ad hoc work between ieDeA and 
the wHO. The wHO was seeking to formally collaborate with 
ieDeA so that up-to-date ieDeA data and analyses could con-
tribute in a predictable and sustainable way to wHO annual global 
Hiv progress reporting and guideline development. The wHO 
wanted to rapidly assess implementation of new Hiv policy 
recommendations, and identify and characterise gaps in the 
response, which randomised control trials and observational studies 
based on outdated data cannot address. The ieDeA Southern 
Africa region was awarded an NiH grant supplement to fund a 
part-time project manager to initiate, plan and develop a formal 
collaboration between the ieDeA consortium and the wHO.
At that time, UNAiDS had just released ambitious 90-90-90 
fast-track targets: 90% of all people living with Hiv know their 
status, 90% of people diagnosed with Hiv are on sustained ART, 
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Table 1. Analysis of data from ieDeA to inform progress on 90-90-90 targets
90-90-90 target Analyses performed Data sources
First 90: 90% of all people living with 
Hiv know their status
No data available in ieDeA None
Second 90: 90% of people diagnosed 
with Hiv are on sustained ART
Analyses of CD4 cell counts at the start of ART [29–31] All seven ieDeA regions, 
ART-CC, COHeRe, NiSDi, 
PHACS and iMPACCT
Analysis of delays from enrolment in Hiv care to ART 
initiation and the influence and impact of ART guideline 
changes among adults and children [32,33]
All seven ieDeA regions
Analysis of retention in care, mortality and loss to follow-up 
among Hiv-infected children and adults on ART [34]
All seven ieDeA regions
Third 90: 90% of all people receiving 
ART are virally suppressed
Analysis of routine viral load data to assess viral suppression 
among adults and children within the first 3 years after 
initiating ART [35]
All seven ieDeA regions
ART: antiretroviral therapy; ART-CC: ART Cohort Collaboration; COHeRe: Collaboration of Observational Hiv epidemiological Research europe in euroCoord; 
iMPAACT: international Maternal Pediatric Adolescent AiDS Clinical Trials Group; NiSDi: NiCHD Site Development initiative; PHACS: Pediatric Hiv/AiDS Cohort 
Study.
months from data collection. Over the years, these analyses have 
supported three wHO global progress reports. Several analyses 
have also supported the development of wHO guidelines; these 
are summarised in a separate article in this supplement [37].
Project organisation and management
More than 65 ieDeA regional investigators across the seven ieDeA 
regions, 10 representatives of the NiH funding institutions, and 
nine wHO staff members have been involved with this collabora-
tion since its inception. The collaboration project manager liaised 
between the ieDeA network and the wHO, and provided updates 
on work and progress in monthly ieDeA working group confer-
ence calls and by email. ieDeA held project debriefs to discuss 
and evaluate the process and work of the collaboration following 
publication of the annual wHO progress reports.
ieDeA multiregional data are only available after review and 
approval of a concept proposal by the ieDeA executive Commit-
tee. This committee is composed of principal investigators from 
the seven ieDeA regions and representatives of the NiH funding 
institutions, including the National institute of Allergy and infec-
tious Diseases, the eunice Kennedy Shriver institute on Child 
Health and Human Development, the National Cancer institute, 
the National institute of Mental Health and the National institute 
on Drug Abuse. For each iteration of the above analyses, ieDeA, 
in consultation with the wHO, drafted new concept proposals 
that were reviewed by the ieDeA Strategic Data working Group 
(wG) prior to submission to the executive Committee. The Stra-
tegic Data wG holds monthly conference calls to promote and 
guide ieDeA multiregional research conducted in collaboration 
with external partners, and consists of representatives from each 
ieDeA region and programme staff from the NiH and the wHO. 
Following executive Committee approval, the concept proposal 
teams worked with the ieDeA Data Harmonization wG, comprised 
of ieDeA regional data managers and analysts, to clarify data 
elements and organise data transfer.
To help navigate, streamline and facilitate ieDeA procedures, a 
timeline was drafted, outlining deliverables and deadlines to ensure 
research occurred in a timely manner and aligned with the timeline 
for the development of annual wHO Progress Reports. ieDeA 
also undertook efforts to synchronise and increase the frequency 
of data collection to ensure that the most up-to-date data were 
available for these purposes.
longitudinal data and accompanying facility information, ieDeA 
can monitor and examine temporal trends in patient care uptake 
and outcomes, and the impact of Hiv guideline changes.
Progress towards the second 90 target was evaluated by two 
multiregional ieDeA-wHO analyses that focused on the pre-ART 
care cascade, and assessed delays from linkage to and enrolment 
in Hiv care to ART initiation and the influence and impact of 
ART guideline changes among adults and children, separately 
[32,33]. The ieDeA west Africa data centre undertook the mul-
tiregional analysis that focused on children, and the ieDeA Central 
Africa data centre performed the multiregional analysis on adults. 
These analyses were undertaken in 2015, 2016 and 2017. The 
ieDeA Central Africa team additionally collaborated with the wHO 
to collect historical data on country-level ART guideline expan-
sions by searching the internet for national ART policies and 
contacting ieDeA and wHO in-country experts.
A third ieDeA-wHO analysis described retention in care, mortality 
and loss to follow-up among children and adults living with Hiv 
on ART, and compared outcomes under different ART eligibility 
guidelines to examine whether people who start ART remain on 
ART [34]. This multiregional analysis was performed at the ieDeA 
Southern Africa data centre in 2015, 2016 and 2017. A fourth 
ieDeA-wHO analysis assessed outcomes in younger (10–14 years 
of age) and older (15–19 years of age) adolescents to provide 
insights into long-term retention for the mixed population of 
perinatally and behaviourally infected youth. The ieDeA Asia-
Pacific data centre undertook this analysis in 2016. The last core 
multiregional analysis of the collaboration used ieDeA routine 
viral load data to assess viral suppression (<1000 copies/mL) 
among adults and children within the first 3 years after initiating 
ART [35]. This multiregional analysis was undertaken in 2015 
and 2017 by the ieDeA Asia-Pacific data centre. Additionally, 
one analysis took advantage of South Africa’s National Population 
Register, with nearly complete enumeration of deaths and extensive 
long-term follow-up data of patients on ART, to assess advances 
in life expectancy over time [36]. The ieDeA Southern Africa 
data centre performed this analysis in 2015 using data from 
South African cohorts.
Since the ieDeA-wHO collaboration began, ieDeA has produced 
12 multiregional analyses and one region-specific analysis – an 
average of four analyses per year using newly reported ieDeA data. 
The wHO received a summary report for each analysis within 6 
Review Journal of Virus Eradication 2018; 4 (Supplement 2): 9–15
12 e Zaniewski et al.
Reports and publications
The results from the ieDeA-wHO collaboration analyses were 
presented in two wHO reports and several academic publications.
The Global health sector response to HIV, 2000–2015: focus on 
innovations in Africa was the 2015 wHO global Hiv progress 
report released in November of that year [3]. The report relied 
on evidence produced by the ieDeA-wHO collaboration to high-
light gaps between Hiv diagnosis and treatment initiation. evidence 
on over 800,000 adults from 10 African countries enrolled in 
ieDeA clinics from 2004 to 2014 showed that about 22% of 
adults were lost to follow-up before initiating ART. Despite this 
shortfall, ieDeA data indicated a steady shift towards earlier enrol-
ment in Hiv care as illustrated in a graph showing increasing 
median CD4 cell count at enrolment in Hiv care across ieDeA 
programmes from 2004 to 2014. The report stressed the impor-
tance of retention in care and the need to retain more people 
on ART. it highlighted another collaboration analysis that found 
only 45% of adults on ART in ieDeA achieved viral suppression 
after 3 years, increasing to over 92% when excluding losses to 
follow-up and deaths. A graph showing the declining proportion 
of people on ART retained in care during the first 5 years, and 
across ieDeA regions, provided further evidence of high attrition 
(Figure 2).
The 2016 wHO global Hiv progress report Prevent HIV, test and 
treat all – WHO support for country impact, published in November 
2016, focused on the latest wHO recommendation to initiate all 
people living with Hiv on ART regardless of CD4 cell count or 
clinical stage [4]. This report highlighted key gaps in achieving 
the ‘treat all’ recommendation, including linkage from testing to 
treatment, citing the ieDeA-wHO collaboration’s latest findings 
on delays from enrolment in Hiv care to ART initiation in adults. 
Despite these challenges, the report found people have been 
starting ART earlier and at higher CD4 cell counts, as illustrated 
in a figure showing increasing median CD4 cell count at ART 
initiation at ieDeA clinics up to 2015 (Figure 3). This report also 
highlighted another collaboration analysis as evidence that a high 
level of viral suppression can be achieved, even in resource-limited 
settings.
At present, the collaboration is undertaking four multiregional 
cascade analysis updates to assess the impact of recent guideline 
changes and progress towards the 90-90-90 targets across all age 
groups, to support the 2018 wHO global progress report that 
is currently under development for release at the end of 2018.
Beyond supporting wHO, these analyses have also generated 14 
abstracts presented at international research conferences, includ-
ing the international workshop on Hiv and Hepatitis Observational 
Databases (iwHOD), CROi, the international AiDS Society confer-
ences, and Australian Hiv and AiDS conferences. Several col-
laborative analyses have also been published in peer-reviewed 
journals including AIDS, Journal of Acquired Immune Deficiency 
Syndromes, Journal of the International AIDS Society and PLoS 
Medicine [32–36].
Discussion
Over the past 4 years, ieDeA has produced 13 analyses based 
on ieDeA multiregional cohort data to support wHO Hiv guideline 
development and ART progress reporting. evidence from ieDeA 
contributed to the 2015 and 2016 wHO global Hiv progress 
reports and two wHO Hiv guideline updates. Research evidence 
from these analyses also informed audiences outside of the wHO. 
Fourteen oral abstract presentations and posters were presented 
at international Hiv conferences and workshops. The five core 
analyses and the one regional analysis have also resulted in five 
peer-reviewed publications [32–36].
The ieDeA-wHO collaboration is an example of a research-policy 
partnership overcoming barriers that often hinder the rapid uptake 
and integration of research evidence into policy development 
[12,14,16,38]. increased interaction and regular communication 
strengthened links between ieDeA and wHO, as each became 
more aware of how ieDeA could be a resource to wHO and vice 
versa. Opportunities for discussion of upcoming wHO policy 
agendas led to more policy-framed, relevant and timely ieDeA 
research. The science has also been strengthened through this 
opportunity for the wHO and ieDeA research teams to com-
municate on the strengths and weaknesses of reporting indicators. 
The collaboration also provided the wHO with more timely access 
to the latest ieDeA scientific evidence, as it was shared with 
them prior to peer-review publication. efforts to synchronise and 
accelerate data extraction in ieDeA resulted in more timely and 
up-to-date data that benefited the collaboration work as well as 
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Figure 2. ieDeA evidence included in WHO Global Health Sector Response to HIV, 2000–2015: Focus on Innovations in Africa, published November 2015 [3]. Retention rates of 
people on ART in the first 5 years after initiating ART between 2009 and 2014 in ieDeA.
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other multiregional research. The collaboration timelines ensured 
ieDeA procedures were navigated efficiently, allowing analyses 
to be completed annually. This research-policy partnership pro-
vided a unique opportunity for the wHO to monitor current 
implementation progress of their action-oriented guidelines and 
for ieDeA to produce more innovative policy-relevant observational 
research evidence.
Although ieDeA successfully produced and shared multiregional 
analyses with wHO, combining large volumes of data from such 
a wide range of settings on tight timelines can present a number 
of challenges. issues of missing data on key variables, and varying 
definitions and data collection protocols, led to a duplication of 
time-consuming data cleaning efforts undertaken simultaneously 
by research teams. inconsistent data distribution and a large 
variability in the volume of data across regions, due to the uneven 
burden of disease and temporal trends, limited the ability to 
provide region-specific and age-specific stratified estimates, 
complicating the interpretation of findings. Service delivery models, 
clinical protocols, standards of care, monitoring schedules and 
efforts in place to trace patients lost to follow-up also vary widely. 
The tight timeline dictated by the wHO publication schedule 
increased and concentrated the workload of ieDeA regional data 
managers responsible for preparing and transferring data for up 
to five separate research proposals requesting varying data ele-
ments and eligibility criteria within the same timeframe, and 
alongside other regional and multiregional data requests, each 
year. However, engagement with wHO also highlighted areas 
where ieDeA and its data workflows could be improved or made 
more efficient.
Data and structural challenges experienced in this collaboration 
with wHO propelled ieDeA to develop and implement improve-
ments to expand and increase data collection and analytic capac-
ity. The Strategic Data wG was established in the second year 
of the collaboration to facilitate regular dialogue between the 
ieDeA network and the wHO through monthly teleconference 
calls. Data harmonisation improvements were undertaken to 
ensure ieDeA data standards were up-to-date and met current 
multiregional research needs. The ieDeA data exchange stand-
ard (www.ieDeADeS.org) was translated from paper format to 
an online research electronic data capture (ReDcap) database 
to simplify, coordinate and accelerate updates across multiple 
platforms, and enable faster and better data exchange and col-
laborative research [39]. in response to the growing number and 
frequency of multiregional concept proposals, ieDeA developed an 
online review hub to simplify, streamline and expedite the concept 
proposal review and approval process for multiregional research.
Limitations of the data have led ieDeA researchers to develop 
methods and approaches to improve the reliability of findings. 
For example, loss to follow-up can be substantial in ART pro-
grammes with unknown outcomes for patients lost. Analyses of 
programme-level outcomes that are based on patients retained 
in care may be biased in this situation [40]. ieDeA researchers 
developed novel approaches and tools to correct estimates of 
programme-level mortality for loss to follow-up, taking into account 
the results of tracing of patients who were lost to follow-up 
[29,41–44]. For instance, a study in an ieDeA site in Malawi 
found that among patients lost to follow-up, and found to be 
alive on tracing, a majority (56%) were still taking ART, sourced 
from another clinic [45]. Figure 4 shows the results from a recent 
attempt to adjust ART programme-level outcomes for unrecorded 
deaths and transfers among patients lost to follow-up [34]. in 
South Africa, ieDeA investigators took advantage of the nearly 
complete recording of deaths and linked birth, laboratory and 
death registries to improve mortality outcome information among 
patients lost to follow-up [46]. Some ieDeA regions have now 
implemented standardised tracing efforts to bring patients back 
to care and to ascertain outcomes of patients lost to follow-up. 
in the analysis of global trends in CD4 cell count at the start of 
ART, multiple imputation was used to deal with missing CD4 cell 
counts at the start of ART [47]. in the same analysis [47], esti-
mates for world Bank country income groups were weighted by 
the number of patients starting ART in a given country and year 
(as reported by UNAiDS [48]), so that countries with many patients 
were appropriately represented.
Now 12 years old, the ieDeA consortium is uniquely positioned 
to provide operational and clinical research that is highly rel-
evant to wHO policy development and progress reporting. with 
close to two million patients from nearly 500 sites in 46 countries, 
including both high- and low-Hiv burden settings and across 
a range of contexts, ieDeA can assess outcomes at both the 
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individual and programme level. ieDeA site assessment surveys 
can be used to inform implementers and policymakers about site-
level needs and capacity, guideline uptake and implementation, 
patient-level impact of practices on Hiv testing and counsel-
ling, and CD4 and viral load monitoring, and how they evolve 
over time. The diversity of data and the heterogeneity of the 
Hiv epidemic, as well as the ability to perform state-of-the-art 
statistical analyses that improve the reliability of findings, give 
ieDeA substantial ability to generalise findings across a variety 
of care delivery settings and geographic contexts.
Conclusion
The research-policy collaborative partnership between ieDeA and 
wHO allows for a better understanding of current policy priorities 
and data and research limitations, leading to more well-timed 
and policy-relevant research. Regular communication provides a 
pathway to facilitate and expedite exchange of crucial knowledge 
and scientific evidence prior to peer-reviewed publication. Such 
partnerships that promote dialogue between stakeholders should 
be encouraged, to facilitate and improve uptake and integration 
of research evidence, to provide timely and reliable insights into 
progress and challenges in the global response to Hiv, and to 
support the development of health policy.
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